Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial - Concepedia

Concepedia

Publication | Closed Access

Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial

348

Citations

22

References

2016

Year

Scott Gettinger, Lyudmila Bazhenova, Corey J. Langer, Ravi Salgia, Kathryn A. Gold, Rafael Rosell, Alice T. Shaw, Glen J. Weiss, Meera Tugnait, Narayana I. Narasimhan,

The Lancet Oncology

Other MalignanciesMedicinePharmacologyPathologyBronchial NeoplasmAnti-cancer AgentCancer TreatmentOncologyRadiation OncologyLung Cancer

References

	Year	Citations

Page 1

Page 1